285 related articles for article (PubMed ID: 30543736)
21. Nivolumab-induced bullous pemphigoid after radiotherapy and abscopal effect.
Grimaux X; Delva R; Jadaud E; Croue A
Australas J Dermatol; 2019 Aug; 60(3):e235-e236. PubMed ID: 30592031
[No Abstract] [Full Text] [Related]
22. Fatal hyperprogression induced by nivolumab in metastatic renal cell carcinoma with sarcomatoid features: a case report.
Dionese M; Pierantoni F; Maruzzo M; Bimbatti D; Deppieri FM; Maran M; Gardiman MP; Basso U
Anticancer Drugs; 2021 Feb; 32(2):222-225. PubMed ID: 32868643
[TBL] [Abstract][Full Text] [Related]
23. Secondary Adrenal Insufficiency Following Nivolumab Therapy in a Patient with Metastatic Renal Cell Carcinoma.
Seki T; Yasuda A; Oki M; Kitajima N; Takagi A; Nakajima N; Miyajima A; Fukagawa M
Tokai J Exp Clin Med; 2017 Sep; 42(3):115-120. PubMed ID: 28871578
[TBL] [Abstract][Full Text] [Related]
24. Successful treatment of metastatic clear cell carcinoma with nivolumab in a patient receiving dialysis treatment.
Tabei T; Natsume I; Kobayashi K
Int J Urol; 2017 Sep; 24(9):708-710. PubMed ID: 28734029
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Toxicity of Fifth-line Nivolumab in a 15-Year-Old Girl With Metastatic Juvenile Renal Cell Carcinoma.
Akbaraly T; Saguintaah M; Topart D; Sirvent N
J Pediatr Hematol Oncol; 2018 Apr; 40(3):251-252. PubMed ID: 29420369
[No Abstract] [Full Text] [Related]
26. A Patient with Nivolumab-related Fulminant Type 1 Diabetes Mellitus whose Serum C-peptide Level Was Preserved at the Initial Detection of Hyperglycemia.
Yamamoto N; Tsurutani Y; Katsuragawa S; Kubo H; Sunouchi T; Hirose R; Hoshino Y; Ichikawa M; Takiguchi T; Yukawa H; Arioka H; Saitou J; Nishikawa T
Intern Med; 2019 Oct; 58(19):2825-2830. PubMed ID: 31243198
[TBL] [Abstract][Full Text] [Related]
27. Development of bullous pemphigoid following radiation therapy combined with nivolumab for renal cell carcinoma: A case report of abscopal toxicities.
Huynh LM; Bonebrake BT; DiMaio DJ; Baine MJ; Teply BA
Medicine (Baltimore); 2021 Dec; 100(49):e28199. PubMed ID: 34889301
[TBL] [Abstract][Full Text] [Related]
28. NICE Guidance - Nivolumab for previously treated advanced renal cell carcinoma: © NICE (2017) Nivolumab for previously treated advanced renal cell carcinoma.
BJU Int; 2018 Sep; 122(3):362-370. PubMed ID: 30187657
[No Abstract] [Full Text] [Related]
29. [An autopsy case of nivolumab-induced myasthenia gravis and myositis].
Sawai T; Hosokawa T; Shigekiyo T; Ogawa S; Sano E; Arawaka S
Rinsho Shinkeigaku; 2019 Jun; 59(6):360-364. PubMed ID: 31142711
[TBL] [Abstract][Full Text] [Related]
30. An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma.
Zarrabi K; Wu S
Expert Opin Biol Ther; 2018 Jun; 18(6):695-705. PubMed ID: 29782188
[TBL] [Abstract][Full Text] [Related]
31. Safety of nivolumab in metastatic renal cell carcinoma patients: A real-life experience in a Spanish urology setting.
Amores Bermúdez J; Osman García I; Unda Urzáiz M; Jiménez Marrero P; Ledo Cepero MJ; Llarena R; Flores Martín J; Abad Vivas-Pérez JI; Rodrigo Aliaga M; Juarez Soto A
Actas Urol Esp (Engl Ed); 2019 Sep; 43(7):364-370. PubMed ID: 31097211
[TBL] [Abstract][Full Text] [Related]
32. [A CASE OF RENAL CELL CARCINOMA THAT ONCE NIVOLUMAB HAD BEEN EFFECTIVE IN METASTATIC LESION AND MADE PRIMARY TUMOR RESECTABLE].
Tsukahara S; Nagatomi Y; Otsubo S; Hasegawa S
Nihon Hinyokika Gakkai Zasshi; 2019; 110(1):32-35. PubMed ID: 31956216
[TBL] [Abstract][Full Text] [Related]
33. Nivolumab efficacy in leptomeningeal metastasis of renal cell carcinoma: a case report.
Bonomi L; Bettini AC; Arnoldi E; Chirco A; Ghilardi L; Manara O; Roscigno M; Da Pozzo LF; Tondini CA
Tumori; 2020 Dec; 106(6):NP76-NP78. PubMed ID: 32041500
[TBL] [Abstract][Full Text] [Related]
34. Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma.
Sarfaty M; Leshno M; Gordon N; Moore A; Neiman V; Rosenbaum E; Goldstein DA
Eur Urol; 2018 Apr; 73(4):628-634. PubMed ID: 28807351
[TBL] [Abstract][Full Text] [Related]
35. Long-term response to immuno-oncology after discontinuation for immuno-related pneumonia in metastatic renal carcinoma: a case report.
Stellato M; Foderaro S; Tonini G; Vincenzi B; Santini D
Anticancer Drugs; 2022 Jan; 33(1):105-108. PubMed ID: 34232938
[TBL] [Abstract][Full Text] [Related]
36. Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab.
Zahoor H; Barata PC; Jia X; Martin A; Allman KD; Wood LS; Gilligan TD; Grivas P; Ornstein MC; Garcia JA; Rini BI
J Immunother Cancer; 2018 Oct; 6(1):107. PubMed ID: 30333065
[TBL] [Abstract][Full Text] [Related]
37. C-reactive protein can be used to predict the therapeutic effects of nivolumab in patients with metastatic renal cell carcinoma.
Teishima J; Murata D; Hasegawa Y; Moriyama H; Mita K; Matsubara A
Int J Urol; 2019 Nov; 26(11):1076-1077. PubMed ID: 31368187
[No Abstract] [Full Text] [Related]
38. Thiamine deficiency in a patient with recurrent renal cell carcinoma who developed weight loss with normal appetite and loss of energy soon after nivolumab treatment.
Onishi H; Okabe T; Uchida N; Shirotake S; Todo M; Oyama M; Ishida M
Palliat Support Care; 2020 Apr; 18(2):241-243. PubMed ID: 31535612
[TBL] [Abstract][Full Text] [Related]
39. Isolated adrenocorticotropic hormone deficiency induced by nivolumab treatment for advanced gastric cancer.
Namikawa T; Shimizu S; Yokota K; Tanioka N; Fukudome I; Munekage M; Uemura S; Maeda H; Kitagawa H; Hanazaki K
Clin J Gastroenterol; 2021 Aug; 14(4):988-993. PubMed ID: 33715100
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature.
Vitale MG; Baldessari C; Milella M; Buti S; Militello AM; Di Girolamo S; Fornarini G; Perri G; Basso U; Maruzzo M; Porta C; Cosmai L; Pipitone S; Cerma K; Cascinu S; Sabbatini R
Clin Genitourin Cancer; 2019 Oct; 17(5):e903-e908. PubMed ID: 31375351
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]